Leerink Partners maintains Outperform rating on United Therapeutics, $725 price target

United Therapeutics (UTHR) received FDA clearance to start the SUMMIT trial for treprostinil SMI in PH-COPD. The phase 2 study will assess safety and tolerability in 40 patients. UTHR aims to begin a phase 3 study in 2028 if successful. The stock is currently trading at $537.77, up 0.87%.

United Therapeutics (UTHR) received FDA clearance to start the SUMMIT trial for treprostinil SMI in PH-COPD. The phase 2 study will assess safety, tolerability, and efficacy in 40 patients. If successful, a phase 3 trial is anticipated in 2028. The company expects significant growth if approved, targeting a larger patient population than current therapies.

United Therapeutics (UTHR) received FDA clearance to start the SUMMIT trial for treprostinil SMI in PH-COPD. The phase 2 study will assess safety and tolerability in 40 patients. If successful, a phase 3 study is expected in 2028. UTHR shares closed at $533.12.

United Therapeutics is developing a soft mist inhaler (SMI) for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The phase 2 SUMMIT study will evaluate the safety and efficacy of treprostinil SMI in 40 patients. If successful, the company plans a phase 3 study in 2028. United Therapeutics anticipates significant growth if the therapy gains FDA approval, potentially treating a larger patient population than its current therapies.

Liquidia (LQDA) shares rebounded 25% after settling a legal dispute with United Therapeutics (UTHR). LQDA agreed to pay $380.7M, remove a PH-ILD indication from Yutrepia, and focus on PAH. Analysts had mixed views, with some calling it favorable for LQDA and others for UTHR. Yutrepia's Q3 sales were $222.7M, up 31% from Q2.

Liquidia and United Therapeutics settled a legal dispute, allowing Yutrepia to remain available for PAH patients but not for PH-ILD. Liquidia will pay $380.7 million and stop marketing Yutrepia for PH-ILD, according to the agreement. The FDA had previously approved Yutrepia for both conditions.